Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma

Summary. Mantle cell lymphoma (MCL) is a non‐Hodgkin's lymphoma of B‐cell lineage. The blastoid variant of MCL, characterized by high mitotic rate, is clinically more aggressive than common MCL. We used the cDNA array technology to examine the gene expression profiles of both blastoid variant and common MCL. The data was analysed by regression analysis, principal component analysis and the naive Bayes' classifier. Eight genes were identified as differentially deregulated between the two groups. Oncogenes CMYC, BCL2 and PIM1 were upregulated more frequently in the blastoid variant than in common MCL. This implied that the gp130‐mediated signal transducer and activator of transcription 3 (STAT3) signalling pathway was involved in the blastoid variant transformation of MCL. Other differentially deregulated genes were TOP1, CD23, CD45, CD70 and NFATC. By using the eight differentially deregulated genes, we created a classifier to distinguish the blastoid variant from common MCL with high accuracy. We also identified 18 genes that were deregulated in both groups. Among them, BCL1, CALLA/CD10 and GRN were suggested to be oncogenes. The products of RGS1, RGS2, ANX2 and CD44H were suggested to promote tumour metastasis. CD66D was suggested to be a tumour suppressor gene.

[1]  J. Cyster,et al.  RGS Molecule Expression in Murine B Lymphocytes and Ability to Down-Regulate Chemotaxis to Lymphoid Chemokines1 2 , 2000, The Journal of Immunology.

[2]  Bonnie F. Sloane,et al.  Human Procathepsin B Interacts with the Annexin II Tetramer on the Surface of Tumor Cells* , 2000, The Journal of Biological Chemistry.

[3]  M. Seto,et al.  Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. , 2000, Blood.

[4]  H. Döhner,et al.  Mantle cell lymphoma is characterized by inactivation of the ATM gene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Bonnie F. Sloane,et al.  Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. , 2000, Biochimica et biophysica acta.

[6]  C. Moratz,et al.  Regulator of G Protein Signaling 1 (RGS1) Markedly Impairs Giα Signaling Responses of B Lymphocytes , 2000, The Journal of Immunology.

[7]  T. Hirano,et al.  Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. , 1999, Immunity.

[8]  K. Zeller,et al.  Function of the c-Myc oncogenic transcription factor. , 1999, Experimental cell research.

[9]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[10]  H. Schwarz,et al.  Analysis of Cd44-Containing Lipid Rafts , 1999, The Journal of cell biology.

[11]  R. V. van Lier,et al.  Aberrant expression and reverse signalling of CD70 on malignant B cells , 1999, British journal of haematology.

[12]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.

[13]  S. Hilsenbeck,et al.  Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. , 1999, Journal of the National Cancer Institute.

[14]  K. Franssila,et al.  Molecular characterization of deletion at 11q22.1‐23.3 in mantle cell lymphoma , 1999, British journal of haematology.

[15]  H. Döhner,et al.  Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. , 1999, Blood.

[16]  T. Hirano,et al.  Stat3 Is Required for the Gp130-mediated Full Activation of the C-myc Gene , 1999 .

[17]  E. Butcher,et al.  Regulation of Chemotactic and Proadhesive Responses to Chemoattractant Receptors by RGS (Regulator of G-protein Signaling) Family Members* , 1998, The Journal of Biological Chemistry.

[18]  P. Herrlich,et al.  The CD44 protein family: roles in embryogenesis and tumor progression. , 1998, Frontiers in bioscience : a journal and virtual library.

[19]  E. Campo,et al.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. , 1998, Blood.

[20]  B. Obrink,et al.  CEA adhesion molecules: multifunctional proteins with signal-regulatory properties , 1997, Current Opinion in Cell Biology.

[21]  C. Wood,et al.  Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains , 1997, Oncogene.

[22]  H. Müller-Hermelink,et al.  Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. , 1997, Blood.

[23]  C. Dinney,et al.  Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model. , 1996, Cancer research.

[24]  H. Erickson,et al.  Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. , 1996, Molecular biology of the cell.

[25]  W. Chan,et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.

[26]  R. V. van Lier,et al.  Identification of a novel subpopulation of germinal center B cells characterized by expression of IgD and CD70 , 1996, European journal of immunology.

[27]  N. Beauchemin,et al.  Inhibition of colonic tumor cell growth by biliary glycoprotein. , 1995, Oncogene.

[28]  Thomas,et al.  Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. , 1995, Cancer research.

[29]  B. Nathwani,et al.  A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. , 1995, Blood.

[30]  K. Hajjar,et al.  An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. , 1994, The Journal of biological chemistry.

[31]  H. Müller-Hermelink,et al.  The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl‐1 gene and high proliferation indices , 1994, Histopathology.

[32]  N. Harris,et al.  Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. , 1993, American journal of clinical pathology.

[33]  Anton Berns,et al.  Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.

[34]  E. Jaffe,et al.  Lymphocytic Lymphoma of Intermediate Differentiation: Morphologic and Immunophenotypic Spectrum and Clinical Correlations , 1990, The American journal of surgical pathology.

[35]  F. Sigaux,et al.  The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Lohuizen,et al.  Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice , 1989, Nature.

[37]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[38]  E. Jaffe,et al.  Lymphocytic lymphoma of intermediate differentiation--mantle zone lymphoma: a distinct subtype of B-cell lymphoma. , 1987, Human pathology.

[39]  Shigeo Abe DrEng.  Pattern Classification , 2001, Springer London.

[40]  K. Franssila,et al.  Deletions at 11q23 in different lymphoma subtypes. , 2000, Haematologica.

[41]  A. Brinkmann,et al.  Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method , 2000, British Journal of Cancer.

[42]  David G. Stork,et al.  Pattern Classification (2nd ed.) , 1999 .

[43]  J. Kehrl,et al.  Heterotrimeric G protein signaling: roles in immune function and fine-tuning by RGS proteins. , 1998, Immunity.

[44]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[45]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[46]  K. Kohn,et al.  Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors , 1994 .

[47]  F. Grunert,et al.  Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives , 1991, Journal of clinical laboratory analysis.